Red warning proposed on cough syrups for children under four

India's drug regulator is considering a red warning on cough syrup labels stating the medicine should not be used in children below four years, The Economic Times reported on Saturday. The proposal, placed before the Drugs Consultative Committee, also suggests a pictorial depiction of school-age children and seeks an amendment to Rule 96 of the Drugs Rules, 1945. In October 2025, the DGHS advised against prescribing cough and cold medicines to children below two years.

Written by AI from Business Standard · not yet reviewed by an editor · Published 19 Sept 2026, 11:28 am IST

Source

Business Standard · read the original report ↗

#cough syrup#cdsco#drug labelling#child health#regulation

Desk check · compared with the source

What the desk checked (5)

India's drug regulator is considering a red warning on cough syrup labels against use in children below four years. — Attributed in source to an Economic Times report published Saturday; framed as a proposal, not a decision.
The proposal before the Drugs Consultative Committee seeks an amendment to Rule 96 of the Drugs Rules, 1945, and includes a pictorial depiction of school-age children. — Specific rule and details appear in the source, credited to the ET report.
In October 2025, DGHS advised against prescribing cough and cold medicines to children below two years. — Figure and date appear in source, attributed to DGHS advisory.
A CDSCO internal technical committee examined a complaint in April 2026 and recommended consulting ICMR, which said it was not working on cough-syrup labelling. — Stated in source via the ET report; dates as given, not independently verifiable here.
An August 22 health ministry notification required warnings on FDCs containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four. — Attributed to the health ministry notification; year of the notification is not specified in the source.

Written by AI from Business Standard · not yet reviewed by an editor · How we use AI · Report an error

Analysts’ view opinion

AI Policy Analyst

This is regulation by label rather than by restriction — and that choice tells you a lot about the design. Instead of banning paediatric cough syrups outright, the regulator is considering a red-ink warning plus a pictorial cue on the bottle, which shifts the decision point to the pharmacy counter and the parent. It is a lighter-touch, cheaper instrument than a product ban, but it also leans on the weakest link in India's medicines chain: over-the-counter dispensing and self-medication habits that advisories have repeatedly failed to change.

The sequence matters: a DGHS advisory in October 2025 against cough and cold medicines for under-twos, then FDC-specific label warnings in August 2026's notification framework for under-fours, and now a broader rule change — suggesting earlier softer measures did not fully achieve compliance.
The move from advisory to an amendment of Rule 96 of the Drugs Rules, 1945 is significant because advisories are persuasive while rules are enforceable against manufacturers.
The pictorial depiction of school-age children is a nod to low-literacy and rushed-purchase realities, borrowing from the public-health playbook used on other consumer warnings.
There is a design gap worth flagging: the proposal targets labels, not prescribing behaviour, even though the complaint that triggered the CDSCO review concerned continued prescribing to infants below two.
The story itself records an evidence-base weakness — the technical committee wanted ICMR input, and ICMR said it was not working on cough-syrup labelling, leaving the measure resting on expert committee judgement rather than fresh domestic research.

What to watch — Watch whether the DCC clears the Rule 96 amendment and how the age threshold is finally set — under-two, under-four, or a tiered warning — and whether any parallel push follows on prescriber and chemist compliance.

This is a proposal at the consultative stage reported by a news outlet, not a notified rule; the story does not establish that it will be approved, in what form, or what timeline and enforcement mechanism would apply.

Deep dive

Research brief · 8 facts · 4 dates · exam-ready

The brief

Context

India's drug regulator is weighing a mandatory red warning on cough syrup labels saying the medicine must not be used in children below four years of age, along with a pictorial depiction of school-age children to signal the product is for older children. The proposal, reported by The Economic Times, is before the Drugs Consultative Committee (DCC) and would need an amendment to Rule 96 of the Drugs Rules, 1945. It follows a series of regulatory steps on paediatric cough and cold medicines, including a DGHS advisory in October 2025 against prescribing such medicines to children under two, and an August 22 notification restricting certain fixed-dose combinations in children below four.

Key facts

The proposed label text reads: 'WARNING: Cough syrup should not be used in children below 4 years of age,' to be displayed in red on the bottle label.
The proposal also seeks a pictorial depiction of school-age children on labels to discourage use in infants and toddlers.
Implementation would require an amendment to Rule 96 of the Drugs Rules, 1945, after deliberation by the Drugs Consultative Committee (DCC).
In October 2025, the Directorate General of Health Services (DGHS) advised judicious prescribing of cough and cold medicines in paediatric care and against their use in children below two years.
In April 2026, an internal technical committee of the CDSCO examined a complaint on continued prescribing of cough syrups to infants below two years.
The CDSCO committee recommended consulting ICMR and holding stakeholder consultations on regulatory and marketing feasibility of labelling changes.
ICMR said it was not undertaking any work on cough-syrup labelling, according to the ET report.
An August 22 health ministry notification required manufacturers of FDCs containing chlorpheniramine maleate and phenylephrine hydrochloride to warn against use in children below four years on the label, package insert and promotional literature.

Timeline

October 2025DGHS advises judicious prescribing of cough and cold medicines in paediatric care and against prescribing them to children below two years.
April 2026CDSCO internal technical committee examines a complaint on continued prescribing of cough syrups to infants below two; recommends ICMR consultation and stakeholder consultations.
August 22 (notification)Health ministry restricts FDCs of chlorpheniramine maleate and phenylephrine hydrochloride in children below four, mandating warnings on label, insert and promotional literature.
Reported Saturday (ET report)Proposal for a red warning against use in children below four years placed before the Drugs Consultative Committee.

Who has a stake

Drugs Consultative Committee (DCC) — Must deliberate on the labelling proposal before any amendment to the Drugs Rules, 1945 proceeds.
Central Drugs Standard Control Organisation (CDSCO) — Its internal technical committee examined the complaint and recommended consultations on labelling feasibility.
Directorate General of Health Services (DGHS) — Issued the October 2025 advisory limiting cough and cold medicine use in young children.
Indian Council of Medical Research (ICMR) — Was recommended for consultation but said it is not working on cough-syrup labelling.
Pharmaceutical manufacturers — Face labelling, package insert and promotional literature changes, and marketing feasibility concerns.
Parents and young children — Directly affected by clarity of warnings on whether cough syrups are safe for infants and toddlers.
Health ministry and Drugs Technical Advisory Board — Issued and recommended the August 22 FDC restriction for children below four years.

Why it matters

Cough and cold syrups are widely used self-medication products in India, and infants and toddlers are most vulnerable to harm from inappropriate dosing. A red, pictorial warning mandated in law would move the safeguard from advisories to enforceable labelling, covering cough syrups broadly rather than only specific fixed-dose combinations.

UPSC angle

Prelims pointers

Rule 96 of the Drugs Rules, 1945 governs labelling requirements; the proposed warning requires its amendment.
Drugs Consultative Committee (DCC) is the forum examining the labelling proposal.
DGHS advisory of October 2025: no cough and cold medicines for children below two years.
August 22 notification: FDCs of chlorpheniramine maleate and phenylephrine hydrochloride barred for children under four.
The August 22 restriction followed recommendations of an expert committee and the Drugs Technical Advisory Board (DTAB).
CDSCO is India's central drug regulator; ICMR is the apex biomedical research body.

Mains framing

India's regulatory response to paediatric cough syrup use has evolved from soft advisories to binding label restrictions. The October 2025 DGHS advice against prescribing cough and cold medicines to children below two, and the August 22 notification restricting fixed-dose combinations of chlorpheniramine maleate and phenylephrine hydrochloride in under-fours, indicate that persuasion alone has not curbed prescribing to infants — a CDSCO technical committee in April 2026 had to examine a fresh complaint on continued prescribing below two years. The current proposal before the DCC, requiring a red warning plus a pictorial cue of school-age children and an amendment to Rule 96 of the Drugs Rules, 1945, would apply across cough syrups rather than to select formulations, marking a shift toward population-level risk communication. Gaps remain: ICMR has said it is not working on cough-syrup labelling, and manufacturers' regulatory and marketing feasibility concerns must be addressed through stakeholder consultation. The way forward lies in completing the DCC and rule-amendment process, coupling labelling with prescriber and pharmacist compliance, and ensuring warnings are legible and understood by caregivers who self-medicate.

Key terms

Drugs Consultative Committee (DCC): Statutory advisory body deliberating the proposed cough syrup labelling change before rule amendment.
Rule 96, Drugs Rules, 1945: Provision on drug labelling that would need amendment to mandate the proposed red warning.
CDSCO: Central Drugs Standard Control Organisation, India's central drug regulatory authority.
Fixed-dose combination (FDC): A medicine combining two or more active ingredients in fixed proportions, such as chlorpheniramine maleate with phenylephrine hydrochloride.
DGHS: Directorate General of Health Services, which advised in October 2025 against cough and cold medicines for children below two.
Drugs Technical Advisory Board (DTAB): Expert body whose recommendations underpinned the August 22 FDC restriction for children under four.

Practice questions

Discuss the adequacy of labelling-based regulation in curbing inappropriate paediatric use of cough and cold medicines in India.
Examine the roles of CDSCO, DCC and DTAB in India's drug regulatory architecture, with reference to recent action on cough syrups.
Why have advisories on paediatric cough syrup use proved insufficient, and what enforcement measures could complement mandatory warnings?

Grounded only in the source report — figures and dates are the source's, not inferred.

Next storyAnalysis: Nexperia dispute holds lessons for Europe's economic security →

← All stories